Details for Patent: 7,943,661
✉ Email this page to a colleague
Which drugs does patent 7,943,661 protect, and when does it expire?
Patent 7,943,661 protects IQIRVO and is included in one NDA.
This patent has thirty patent family members in twenty-three countries.
Recent additions to Drugs Protected by US Patent 7,943,661
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | IQIRVO | elafibranor | TABLET | 218860 | Jun 10, 2024 | RX | Yes | 7,943,661 | Y | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 7,943,661
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | IQIRVO | elafibranor | TABLET;ORAL | 218860-001 | Jun 10, 2024 | RX | Yes | Yes | 7,943,661 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,943,661
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E365703 | ⤷ Subscribe | |||
Australia | 2003264698 | ⤷ Subscribe | |||
Brazil | 0312398 | ⤷ Subscribe | |||
Brazil | PI0312398 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |